Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy

Chronic kidney disease: global dimension and perspectives

(2013) Vivekanand Jha et al.   LANCET

CKD273, a New Proteomics Classifier Assessing CKD and Its Prognosis

(2013) Àngel Argilés et al.   PLoS One

Technical aspects and inter-laboratory variability in native peptide profiling: The CE–MS experience

(2012) Harald Mischak et al.   CLINICAL BIOCHEMISTRY

Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy

(2012) P. Zurbig et al.   DIABETES

A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus

(2012) S. S. Roscioni et al.   DIABETOLOGIA

Implementation of proteomic biomarkers: making it work

(2012) Harald Mischak et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases

(2012) L. Molin et al.   Journal of Proteomics

Mechanisms and Treatment of CKD

(2012) P. Ruggenenti et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

How to get proteomics to the clinic? Issues in clinical proteomics, exemplified by CE-MS

(2012) Harald Mischak   Proteomics Clinical Applications

Addressing the Challenge of Defining Valid Proteomic Biomarkers and Classifiers

(2011) Mohammed Dakna et al.   BMC BIOINFORMATICS

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

(2011) Goodarz Danaei et al.   LANCET

Human urinary peptide database for multiple disease biomarker discovery

(2011) Justyna Siwy et al.   Proteomics Clinical Applications

Debate: CON Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial

(2010) Richard J. Glassock   AMERICAN JOURNAL OF NEPHROLOGY

Debate: PRO Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial

(2010) Hiddo J. Lambers Heerspink et al.   AMERICAN JOURNAL OF NEPHROLOGY

Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease

(2010) David M. Good et al.   MOLECULAR & CELLULAR PROTEOMICS

Recommendations for Biomarker Identification and Qualification in Clinical Proteomics

(2010) H. Mischak et al.   Science Translational Medicine

In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria

(2009) Bruce A. Perkins et al.   KIDNEY INTERNATIONAL

Identification and Validation of Urinary Biomarkers for Differential Diagnosis and Evaluation of Therapeutic Intervention in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

(2009) Marion Haubitz et al.   MOLECULAR & CELLULAR PROTEOMICS

Quantitative Urinary Proteome Analysis for Biomarker Evaluation in Chronic Kidney Disease

(2008) Justyna Jantos-Siwy et al.   JOURNAL OF PROTEOME RESEARCH

The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy

(2008) Kasper Rossing et al.   Proteomics Clinical Applications

Discovery and validation of urinary biomarkers for prostate cancer

(2008) Dan Theodorescu et al.   Proteomics Clinical Applications

CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics

(2008) Joshua J. Coon et al.   Proteomics Clinical Applications